FDA issues EUA for intradermal Jynneos vaccine for monkeypox

The US FDA has granted emergency use authorization (EUA) for the Jynneos, the Modified Vaccinia Ankara (MVA) vaccine, for adults aged ≥18 years at high risk for monkeypox infection. The vaccine is generally given in two doses subcutaneously at a gap of 28 days for smallpox and monkeypox. The FDA has now allowed fraction of the dose for intradermal administration to increase the available doses, but retains the effectiveness….(Source: US FDA, Aug. 9, 2022)

Time-restricted eating encourages weight loss

A new 14-week study of 90 people with obesity in JAMA Internal Medicine says that time-restricted eating for 8 hours from 7 am to 3 pm reduced body weight more effectively than eating for ≥12 hours; −6.3 kg vs −4.0 kg, respectively. It also reduced the diastolic BP. However, long-term studies are needed to assess its effectiveness in lowering body fat…(Source: JAMA Internal Medicine, Aug. 8, 2022)

Evaluate all patients with acute anterior uveitis for musculoskeletal symptoms

Patients with acute anterior uveitis often have high prevalence of undiagnosed coexistent spondyloarthritis. More than half (56%) of the patients with acute anterior uveitis were found to also have spondyloarthritis. In 70% of patients, it was detected during the study. Presence of psoriasis, HLA-B27 positivity, raised CRP and male gender were factors that had a positive association with diagnosis of spondyloarthritis… (Source: Arthritis & Rheumatology, July 29, 2022).

Pfizer launches phase 3 trial for Lyme disease vaccine

Pfizer has begun a phase 3 clinical study to test its protein subunit vaccine candidate VLA15 for safety and efficacy against Lyme disease. The multicenter trial is being conducted in Europe and the US and will enroll around 6000 healthy volunteers, both adults and children (≥5 years). The vaccine or saline placebo will be administered in three doses as primary vaccination and a booster dose after one year… (Source: Medscape, Aug. 9, 2022).